Where others have failed will Atl1102 succeed ?, page-922

Harsh but true - Drugbaron's take from above:
_____________________________________

"All this should be chastening to Sarepta management, their investors and even Janet Woodcock who decided to approve Exondys 51 in the absence of evidence of clinical benefit.

What we are observing in these failed trials is not bad luck, but something entirely predictable. And by pursuing these flawed hypotheses, we are doing patients a disservice – no matter how strongly they might argue in support of the research. Resources are drawn away from approaches that may actually stand a chance to work (such as focusing on anti-fibrotic approaches), and precious healthcare dollars are being spent on Disallowed rather than drugs that can make a difference."
________________________________________

Join the dots folks....it's gonna be a great ride over the next 12 months for ANP.